Skip to Content
Biotechnology and health

CRISPR plants won’t be regulated

In a big win for the biotech industry, the US Department of Agriculture says once and for all it won’t regulate plants whose genomes have been altered using gene-editing technology.

Why it’s a field day: The decision means that we could see a boom in newfangled plants from firms like Monsanto, universities, and startups like Calyxt, whose oil-altered soybeans featured in our cover story late last year.

Here’s the logic: The USDA says gene editing is just a (much) faster form of breeding. So long as a genetic alteration could have been bred into a plant, it won’t be regulated. That includes changes that create immunity to disease or natural resistance to crop chemicals, as well as edits to make seeds bigger and heavier. It doesn’t include transgenic plants (those with a gene from a distant species)—those will still be regulated. 

Problems ahead: Trade in major crops is a global affair. Unless Europe and China agree with the US, exports of CRISPR plants could yet be blocked.

Crop Correction: A previous version of this post incorrectly said the USDA had intended to regulate gene-edited plants more aggressively under an Obama-era proposed rule. Not so, says Richard Coker, a USDA spokesman. 

Deep Dive

Biotechnology and health

How scientists traced a mysterious covid case back to six toilets

When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.

An AI-driven “factory of drugs” claims to have hit a big milestone

Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology

The quest to legitimize longevity medicine

Longevity clinics offer a mix of services that largely cater to the wealthy. Now there’s a push to establish their work as a credible medical field.

There is a new most expensive drug in the world. Price tag: $4.25 million

But will the latest gene therapy suffer the curse of the costliest drug?

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.